The
peroxisome proliferator-activated receptor-gamma (
PPAR-gamma) is constitutively expressed in primary cultures of rat microglia, the main population of brain resident macrophages, and its
ligand-dependent activation leads to the repression of several microglial functions. A few non-steroidal anti-inflammatory drugs (
NSAIDs), e.g.
indomethacin and
ibuprofen, show
PPAR-gamma agonistic properties. It has been proposed that
PPAR-gamma activation contributes to the potential benefits of the long-term use of certain
NSAIDs in delaying the progression of
Alzheimer's disease (AD). Previous data have shown that the
NSAID HCT1026 [2-fluoro-alpha-methyl(1,1'-
biphenyl)4-acetic acid-4-(nitrooxy)butyl
ester], a derivative of
flurbiprofen which releases
nitric oxide (NO), reduces the number of reactive microglial cells in a variety of models. This evidence together with the chemical analogy with
ibuprofen led us to investigate whether
flurbiprofen and
HCT1026 interact with
PPAR-gamma and interfere with microglial activation. We found that a low concentration (1 microm) of
HCT1026, but not
flurbiprofen, activated
PPAR-gamma in primary cultures of rat microglia, with kinetics similar to those of the synthetic agonist
ciglitazone. The
PPAR-gamma antagonist
GW9662 (2-chloro-5-nitrobenzanilide) prevented the activation of
PPAR-gamma by
HCT1026. Interestingly, unlike other
NSAIDs that activate
PPAR-gamma at concentrations higher than those required for
cyclooxygenase inhibition,
HCT1026 activated
PPAR-gamma and inhibited
prostaglandin E2 synthesis at the same low concentration (1 microm). The results suggest that
HCT1026 may exert additional anti-inflammatory actions through
PPAR-gamma activation, allowing a more effective control of microglial activation and
brain inflammation.